$FNCH
Finch Therapeutics Group, Inc. Stock $fnch

$fnch Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000095017022005243 Filed on March 31, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021
Revenue	$354.0K	$806.0K	$18.53M
YoY Change	-90.04%	-55.4%	140.08%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.404M	$5.065M	$21.24M
YoY Change	106.68%	-20.51%	51.59%
% of Gross Profit
Research & Development	$15.53M	$14.80M	$57.28M
YoY Change	19.69%	72.73%	72.82%
% of Gross Profit
Depreciation & Amortization	$1.331M	$678.0K	$2.301M
YoY Change	261.68%	213.89%	191.27%
% of Gross Profit
Operating Expenses	$24.93M	$19.87M	$78.52M
YoY Change	42.26%	32.99%	66.51%
Operating Profit	-$24.58M		-$59.99M
YoY Change	75.9%		52.11%
Interest Expense	$13.00K	$8.000K	$22.00K
YoY Change		700.0%	-80.0%
% of Operating Profit
Other Income/Expense, Net	$13.00K	-$29.00K	$1.825M
YoY Change	-285.71%	-154.72%	1821.05%
Pretax Income	-$24.57M	-$19.06M	-$58.16M
YoY Change	75.72%	45.56%	47.84%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$24.57M	-$19.06M	-$58.16M
YoY Change	75.72%	45.56%	47.84%
Net Earnings / Revenue	-6939.83%	-2364.14%	-313.84%
Basic Earnings Per Share	-$0.52		-$1.48
Diluted Earnings Per Share	-$516.9K	-$400.5K	-$1.484M
COMMON SHARES
Basic Shares Outstanding	47.53M	47.48M	39.20M
Diluted Shares Outstanding	47.53M		39.20M

Balance Sheet

Concept	2022 Q1	2021 Q4	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$106.9M	$133.5M	$133.5M
YoY Change	-44.6%		33.88%
Cash & Equivalents	$106.9M	$133.5M	$133.5M
Short-Term Investments
Other Short-Term Assets	$15.55M	$8.576M	$8.576M
YoY Change	418.2%		58.81%
Inventory
Prepaid Expenses
Receivables	$200.0K	$494.0K	$494.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$122.6M	$142.6M	$142.6M
YoY Change	-38.16%	34.27%	34.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.41M	$19.64M	$24.69M
YoY Change	18.06%	180.34%	252.69%
Goodwill	$18.06M	$18.06M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.542M	$4.905M	$7.173M
YoY Change	2002.78%	2352.5%	497.75%
Total Long-Term Assets	$81.98M	$82.82M	$82.82M
YoY Change	21.26%	39.96%	40.13%
TOTAL ASSETS
Total Short-Term Assets	$122.6M	$142.6M	$142.6M
Total Long-Term Assets	$81.98M	$82.82M	$82.82M
Total Assets	$204.6M	$225.4M	$225.4M
YoY Change	-23.06%	36.31%	36.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.765M	$3.737M	$3.737M
YoY Change	22.87%	42.58%	43.73%
Accrued Expenses	$12.02M	$11.05M	$11.05M
YoY Change	155.79%		112.56%
Deferred Revenue		$0.00
YoY Change		-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$16.79M	$14.79M	$14.79M
YoY Change	45.94%	28.77%	28.61%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$7.000K
YoY Change	-100.0%	-100.0%	-99.61%
Other Long-Term Liabilities	$0.00	$7.000K	$4.887M
YoY Change	-100.0%	-96.83%	-56.37%
Total Long-Term Liabilities	$0.00	$7.000K	$4.894M
YoY Change	-100.0%	-99.66%	-62.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.79M	$14.79M	$14.79M
Total Long-Term Liabilities	$0.00	$7.000K	$4.894M
Total Liabilities	$24.84M	$23.15M	$23.15M
YoY Change	-6.24%	-17.35%	-17.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$185.6M	-$161.0M
YoY Change	58.85%	56.56%
Common Stock	$365.4M	$363.2M
YoY Change	2.55%	5003.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$179.8M	$202.2M	$202.2M
YoY Change
Total Liabilities & Shareholders Equity	$204.6M	$225.4M	$225.4M
YoY Change	-23.06%	36.31%	36.34%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021
OPERATING ACTIVITIES
Net Income	-$24.57M	-$19.06M	-$58.16M
YoY Change	75.72%	45.56%	47.84%
Depreciation, Depletion And Amortization	$1.331M	$678.0K	$2.301M
YoY Change	261.68%	213.89%	191.27%
Cash From Operating Activities	-$25.65M	-$13.79M	-$67.13M
YoY Change	68.57%	34.09%	114.28%
INVESTING ACTIVITIES
Capital Expenditures	$909.0K	-$2.002M	-$15.98M
YoY Change	-89.71%	-6.71%	507.72%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$62.00K
YoY Change	-100.0%
Cash From Investing Activities	-$909.0K	-$2.002M	-$15.92M
YoY Change	-89.7%	-6.71%	504.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.000K	70.00K	119.1M
YoY Change	-100.0%	-130.57%	30.21%
NET CHANGE
Cash From Operating Activities	-25.65M	-13.79M	-67.13M
Cash From Investing Activities	-909.0K	-2.002M	-15.92M
Cash From Financing Activities	5.000K	70.00K	119.1M
Net Change In Cash	-26.55M	-15.72M	36.06M
YoY Change	-128.45%	24.19%	-37.31%
FREE CASH FLOW
Cash From Operating Activities	-$25.65M	-$13.79M	-$67.13M
Capital Expenditures	$909.0K	-$2.002M	-$15.98M
Free Cash Flow	-$26.56M	-$11.78M	-$51.15M
YoY Change	10.42%	44.85%	78.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#LiabilitiesCurrent
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001733257
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#LiabilitiesCurrent
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-40227
CY2021	dei	Entity Registrant Name EntityRegistrantName	FINCH THERAPEUTICS GROUP, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3433558
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	200 Inner Belt Road
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Somerville
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02143
CY2021	dei	City Area Code CityAreaCode	617)
CY2021	dei	Local Phone Number LocalPhoneNumber	229-6499
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2021	dei	Trading Symbol TradingSymbol	FNCH
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	354900000
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47532573
CY2021	dei	Auditor Firm AuditorFirmId	34
CY2021	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2021	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	133481000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99710000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	494000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1034000
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	0
CY2020Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	61000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8576000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5359000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	142551000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	106164000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19635000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7004000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5053000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2021Q4	fnch	In Process Research And Development InProcessResearchAndDevelopment	32900000
CY2020Q4	fnch	In Process Research And Development InProcessResearchAndDevelopment	32900000
CY2021Q4	us-gaap	Goodwill Goodwill	18057000
CY2020Q4	us-gaap	Goodwill Goodwill	18057000
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	0
CY2020Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1013000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2268000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4905000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	200000
CY2021Q4	us-gaap	Assets Assets	225369000
CY2020Q4	us-gaap	Assets Assets	165338000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3737000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2621000
CY2021Q4	fnch	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	9925000
CY2020Q4	fnch	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	5228000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1128000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	266000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3371000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14790000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11486000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3461000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3461000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	10260000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1808000
CY2021Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0
CY2020Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	766000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4887000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	221000
CY2021Q4	us-gaap	Liabilities Liabilities	23145000
CY2020Q4	us-gaap	Liabilities Liabilities	28002000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	598232153
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47512182
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47512182
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8391793
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8391793
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	47000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	8000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	363172000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	7109000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-160995000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-102835000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	202224000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-95718000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	225369000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	165338000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18532000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7719000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57279000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33144000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	4161000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	3099000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1808000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21238000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14011000
CY2021	us-gaap	Operating Expenses OperatingExpenses	78517000
CY2020	us-gaap	Operating Expenses OperatingExpenses	47155000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-59985000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-39436000
CY2021	fnch	Gains Losses On Extinguishment Of Debt Includes Accrued Interest GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest	1827000
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	22000
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	106000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	28000
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-13000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-52000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1825000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	95000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-58160000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39341000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58160000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-39341000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-58160000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-39341000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.48
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.83
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39202086
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8144855
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-59535000
CY2020	fnch	Issuance Of Series C Redeemable Convertible Preferred Stock Net Of Issuance Costs Value IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue	59000
CY2020	fnch	Stock Issued During Period Value Vesting Of Restricted Stock StockIssuedDuringPeriodValueVestingOfRestrictedStock	8000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3091000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-39341000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-95718000
CY2021	fnch	Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Upon Initial Public Offering ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering	233053000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	115714000
CY2021	fnch	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Shares AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares	3003
CY2021	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	10000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	181000
CY2021	fnch	Common Stock Warrants Exercised CommonStockWarrantsExercised	19303
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4161000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58160000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	202224000
CY2021	us-gaap	Profit Loss ProfitLoss	-58160000
CY2020	us-gaap	Profit Loss ProfitLoss	-39341000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2301000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	790000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	28000
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-13000
CY2021	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	913000
CY2020	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	0
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-540000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-143000
CY2021	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-61000
CY2020	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-3507000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3217000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3665000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	4689000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2261000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	440000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5435000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	481000
CY2021	fnch	Increase Decrease In Due To Related Parties Current Excluding Accounts Payable IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable	-266000
CY2020	fnch	Increase Decrease In Due To Related Parties Current Excluding Accounts Payable IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable	-68000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-13631000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2963000
CY2021	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0
CY2020	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	309000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1006000
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67133000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31329000
CY2021	fnch	Payments To Acquire Property And Equipment Purchases From Related Party PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty	15983000
CY2020	fnch	Payments To Acquire Property And Equipment Purchases From Related Party PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty	2633000
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	62000
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15921000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2633000
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	118576000
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2021	fnch	Proceeds From Issuance Of Series D Convertible Preferred Stock ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock	0
CY2020	fnch	Proceeds From Issuance Of Series D Convertible Preferred Stock ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock	90000000
CY2021	fnch	Payment Of Redeemable Convertible Preferred Stock Issuance Costs PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts	0
CY2020	fnch	Payment Of Redeemable Convertible Preferred Stock Issuance Costs PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts	96000
CY2021	fnch	Proceeds From Underwriters Exercise Of Overallotment Option Net Of Underwriting Discounts And Commissions And Initial Public Offering Costs ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts	3049000
CY2020	fnch	Proceeds From Underwriters Exercise Of Overallotment Option Net Of Underwriting Discounts And Commissions And Initial Public Offering Costs ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts	0
CY2021	fnch	Principal Payments On Capital Lease Obligation PrincipalPaymentsOnCapitalLeaseObligation	27000
CY2020	fnch	Principal Payments On Capital Lease Obligation PrincipalPaymentsOnCapitalLeaseObligation	47000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	171000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	59000
CY2021	fnch	Proceeds From Paycheck Protection Program Loan ProceedsFromPaycheckProtectionProgramLoan	0
CY2020	fnch	Proceeds From Paycheck Protection Program Loan ProceedsFromPaycheckProtectionProgramLoan	1808000
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2659000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	249000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	119110000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	91475000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	36056000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	57513000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	99909000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	42396000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	135965000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	99909000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	9000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	11000
CY2021	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	1434000
CY2020	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	0
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	381000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1398000
CY2021	us-gaap	Stock Issued1 StockIssued1	233053000
CY2020	us-gaap	Stock Issued1 StockIssued1	0
CY2021	fnch	Operating Right Of Use Assets Obtained In Exchange For New Operating Leases Upon Adoption Of Asc842 OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842	5965000
CY2020	fnch	Operating Right Of Use Assets Obtained In Exchange For New Operating Leases Upon Adoption Of Asc842 OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842	0
CY2021	fnch	Deferred Initial Public Offering Costs In Accounts Payable And Accrued Expenses DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses	0
CY2020	fnch	Deferred Initial Public Offering Costs In Accounts Payable And Accrued Expenses DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses	764000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	133481000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99710000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2484000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	199000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	135965000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	99909000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. NATURE OF OPERATIONS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finch Therapeutics Group, Inc. (the “Company” or “FTG”) was incorporated in 2017 as a Delaware corporation. The Company was formed as a result of a merger and recapitalization of Finch Therapeutics, Inc. (“Finch”) and Crestovo Holdings LLC (“Crestovo”) in September 2017 (the “Merger”), in which the former owners of Finch and Crestovo were issued equivalent stakes in the newly formed company, FTG. Crestovo was renamed Finch Therapeutics Holdings LLC in November 2020 (“Finch Holdings”). Finch and Finch Holdings are both wholly-owned subsidiaries of FTG.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The Company’s Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">is an orally administered complete microbiome therapeutic in development for the prevention of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recurrent </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clostridioides difficile </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection, or CDI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 18, 2021, the Company completed its initial public offering (“IPO”) in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">127.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and offering costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. On April 20, 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">192,877</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of common stock, pursuant to the underwriters’ partial exercise of their overallotment option, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting underwriting discounts, commissions and offering costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the IPO, the Company’s board of directors (the “Board”) and stockholders approved an amended and restated certificate of incorporation to, among other things, effect a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7ea1798d-7710-41a8-88de-a9818d271ecd;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one-for-14.444</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split of the Company’s issued and outstanding shares of common stock and redeemable convertible preferred stock, as well as to effect a proportional adjustment to the existing conversion ratios for the Company’s redeemable convertible preferred stock. The reverse stock split was effected on March 12, 2021. Accordingly, all share and per share amounts of common stock for all periods presented in the accompanying audited consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect this reverse stock split and adjustment of preferred stock conversion ratios. Upon the closing of the IPO, all of the then-outstanding shares of redeemable convertible preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,253,609</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of convertible preferred stock outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risks and Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to a number of risks similar to other companies in its industry, including rapid technological change, the risk that its products will fail to demonstrate efficacy in clinical trials, uncertainty of market acceptance of its products, competition from larger pharmaceutical and biotechnology companies and dependence on key personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The extent of the impact of the COVID-19 pandemic on the Company’s business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak, including with respect to variants of the virus, and its impact on clinical trial enrollment, trial sites, contract research organizations, contract manufacturing organizations, and other third parties with whom the Company does business, as well as its impact on regulatory authorities and its key scientific and management personnel. While the Company is experiencing limited financial impacts at this time, given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company’s business, financial condition and results of operations ultimately could be materially adversely affected. The Company continues to closely</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">monitor the COVID-19 pandemic as it evolves its business continuity plans, clinical development plans and response strategy.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At this time, it is unknown how long the adverse conditions associated with the COVID-19 pandemic will last and what the complete financial effect will be to the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has incurred recurring losses since its inception, including net losses of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the years ended December 31, 2021 and 2020, respectively. In addition, as of December 31, 2021, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">161.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company expects to continue to generate operating losses for the foreseeable future as it continues to develop its product candidates. The Company expects that its cash and cash equivalents of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as of December 31, 2021, will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months beyond the date of issuance the annual consolidated financial statements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company will not generate any future revenue from product sales unless and until it successfully completes clinical development and obtains regulatory approval for one or more of its product candidates. If the Company obtains regulatory approval for any of its product candidates, it expects to incur significant expenses related to developing its internal commercialization capability to support manufacturing, product sales, marketing and distribution. As a result, the Company will need substantial additional funding to support its operating activities as it advances its product candidates through clinical development, seeks regulatory approval, and if any of its product candidates are approved, proceeds to commercialization.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings, debt financings, and license and development agreements in connection with any future collaborations. Adequate funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to obtain funding, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58200000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-39300000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-161000000.0
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	133500000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the pattern and method of recognizing revenue, the accrual of research and development costs, and the annual assessment of impairment of goodwill and in-process research and development assets. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span>
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	133500000
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	99700000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	2500000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	200000
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. As of December 31, 2021 and 2020, the Company’s cash and cash equivalents were held with one financial institution. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.</span>
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2021	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0
CY2020	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0
CY2020Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1000000.0
CY2016Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5800000
CY2016Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	900000
CY2016Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5900000
CY2021Q4	fnch	Derecognition Of Deferred Rent Liabilities DerecognitionOfDeferredRentLiabilities	800000
CY2021Q4	fnch	Unamortization Of Lease Incentives UnamortizationOfLeaseIncentives	200000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	0.50
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18532000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7719000
CY2021Q4	fnch	Transfers Between Fair Value Levels TransfersBetweenFairValueLevels	0
CY2020Q4	fnch	Transfers Between Fair Value Levels TransfersBetweenFairValueLevels	0
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	23861000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9033000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4226000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2029000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19635000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7004000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2300000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	800000
CY2021Q1	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The lease term is from March 2021 through February 2023
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5053000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	22000
CY2021Q4	fnch	Lease Assets LeaseAssets	5075000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1128000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	19000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4887000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7000
CY2021Q4	fnch	Lease Liabilities LeaseLiabilities	6041000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	27000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	10000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1336000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	254000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	525000
CY2021	us-gaap	Sublease Income SubleaseIncome	88000
CY2021	us-gaap	Lease Cost LeaseCost	2064000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M6D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.067
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.306
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1006000
CY2021	fnch	Principal Payments On Capital Lease Obligation PrincipalPaymentsOnCapitalLeaseObligation	27000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1487000
CY2021Q4	fnch	Hood Park Lease Future Minimum Payments Due Current HoodParkLeaseFutureMinimumPaymentsDueCurrent	4535000
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	24000
CY2021Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due Current OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent	6046000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1440000
CY2021Q4	fnch	Hood Park Lease Future Minimum Payments Due In Two Years HoodParkLeaseFutureMinimumPaymentsDueInTwoYears	4663000
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	6000
CY2021Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due In Two Years OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears	6109000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1460000
CY2021Q4	fnch	Hood Park Lease Future Minimum Payments Due In Three Years HoodParkLeaseFutureMinimumPaymentsDueInThreeYears	4795000
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	0
CY2021Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due In Three Years OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears	6255000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1496000
CY2021Q4	fnch	Hood Park Lease Future Minimum Payments Due In Four Years HoodParkLeaseFutureMinimumPaymentsDueInFourYears	4931000
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	0
CY2021Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due In Four Years OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears	6427000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1116000
CY2021Q4	fnch	Hood Park Lease Future Minimum Payments Due In Five Years HoodParkLeaseFutureMinimumPaymentsDueInFiveYears	5071000
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	0
CY2021Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due In Five Years OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears	6187000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0
CY2021Q4	fnch	Hood Park Lease Future Minimum Payments Due Thereafter HoodParkLeaseFutureMinimumPaymentsDueThereafter	27605000
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0
CY2021Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due Thereafter OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter	27605000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	6999000
CY2021Q4	fnch	Hood Park Lease Future Minimum Payments Due HoodParkLeaseFutureMinimumPaymentsDue	51600000
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	30000
CY2021Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue	58629000
CY2021Q4	fnch	Interest Portion Of Operating Leases Future Minimum Payments Due InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue	984000
CY2021Q4	fnch	Hood Park Lease Future Minimum Payments Interest Included In Payments HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments	0
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	5000
CY2021Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Interest Included In Payments OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments	989000
CY2021Q4	fnch	Present Value Of Future Minimum Lease Payments PresentValueOfFutureMinimumLeasePayments	6015000
CY2021Q4	fnch	Hood Park Lease Future Minimum Payments Present Value Of Net Minimum Payments HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments	51600000
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	25000
CY2021Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Present Value Of Net Minimum Payments OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments	57640000
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1351000
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	36000
CY2020Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due Current OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent	1387000
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1387000
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	24000
CY2020Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due In Two Years OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears	1411000
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1424000
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	6000
CY2020Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due In Three Years OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears	1430000
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1460000
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	0
CY2020Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due In Four Years OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears	1460000
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1496000
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	0
CY2020Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due In Five Years OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears	1496000
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1115000
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0
CY2020Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due Thereafter OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter	1115000
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	8233000
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	66000
CY2020Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue	8299000
CY2020Q4	fnch	Interest Portion Of Operating Leases Future Minimum Payments Due InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue	0
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	14000
CY2020Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Interest Included In Payments OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments	-14000
CY2020Q4	fnch	Present Value Of Future Minimum Lease Payments PresentValueOfFutureMinimumLeasePayments	8233000
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	52000
CY2020Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Present Value Of Net Minimum Payments OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments	8285000
CY2021Q4	fnch	Accrued Research And Development AccruedResearchAndDevelopment	1345000
CY2020Q4	fnch	Accrued Research And Development AccruedResearchAndDevelopment	81000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1117000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	711000
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	4401000
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3532000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3062000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	904000
CY2021Q4	fnch	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	9925000
CY2020Q4	fnch	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	5228000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0690
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0604
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0019
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0160
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0212
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0203
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2930
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2696
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0053
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0051
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	48419000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	30192000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4376000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2921000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	3057000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	859000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	225000
CY2021Q4	fnch	Right Of Use Liabilities RightOfUseLiabilities	1633000
CY2020Q4	fnch	Right Of Use Liabilities RightOfUseLiabilities	0
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	548000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	289000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	55835000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	36684000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	49079000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31963000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	6756000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4721000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	7952000
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	7891000
CY2021Q4	fnch	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	563000
CY2020Q4	fnch	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	253000
CY2021Q4	fnch	Right Of Use Asset RightOfUseAsset	1372000
CY2020Q4	fnch	Right Of Use Asset RightOfUseAsset	0
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	330000
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	38000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	10217000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8182000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3461000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3461000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	17100000
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	181900000
CY2020	fnch	Operating Loss Carry Forwards Expiration Year OperatingLossCarryForwardsExpirationYear	2037
CY2021	fnch	Effective Income Tax Rate Reconciliation Tax Credits Research Expiration Date EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate	which will expire at various dates through 2041
CY2020	fnch	Effective Income Tax Rate Reconciliation Tax Credits Research Expiration Date EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate	which will expire at various dates through 2040
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1318000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1004000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	507000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	3000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	314000
CY2021	fnch	Unrecognized Tax Benefits Penalties And Interest Accrued UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued	1822000
CY2020	fnch	Unrecognized Tax Benefits Penalties And Interest Accrued UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued	1318000
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2020Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	451427842
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	31253609
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	31253609
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	233054000
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	219980000
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Each share of common stock entitles the holder to one vote
CY2021	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3309965
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	32326829
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	500000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0088
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0046
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1700000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	400000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.87
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.87
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	547360
CY2021	fnch	Remaining Stock Compensation Expenses RemainingStockCompensationExpenses	0
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4161000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3099000
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	800000
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	400000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58160000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-39341000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-58160000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-39341000
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39202086
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8144855
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.48
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.83
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3309965
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32326829

Files In Submission

Name	View Source	Status
0000950170-22-005243-index-headers.html	Edgar Link	pending
0000950170-22-005243-index.html	Edgar Link	pending
0000950170-22-005243.txt	Edgar Link	pending
0000950170-22-005243-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
fnch-20211231.htm	Edgar Link	pending
fnch-20211231.xsd	Edgar Link	pending
fnch-20211231_cal.xml	Edgar Link	unprocessable
fnch-20211231_def.xml	Edgar Link	unprocessable
fnch-20211231_htm.xml	Edgar Link	completed
fnch-20211231_lab.xml	Edgar Link	unprocessable
fnch-20211231_pre.xml	Edgar Link	unprocessable
fnch-ex10_17.htm	Edgar Link	pending
fnch-ex10_19.htm	Edgar Link	pending
fnch-ex10_20.htm	Edgar Link	pending
fnch-ex10_21.htm	Edgar Link	pending
fnch-ex10_3.htm	Edgar Link	pending
fnch-ex10_7.htm	Edgar Link	pending
fnch-ex21_1.htm	Edgar Link	pending
fnch-ex23_1.htm	Edgar Link	pending
fnch-ex31_1.htm	Edgar Link	pending
fnch-ex31_2.htm	Edgar Link	pending
fnch-ex32_1.htm	Edgar Link	pending
fnch-ex4_3.htm	Edgar Link	pending
img102364508_0.jpg	Edgar Link	pending
img102364508_1.jpg	Edgar Link	pending
img102364508_10.jpg	Edgar Link	pending
img102364508_11.jpg	Edgar Link	pending
img102364508_12.jpg	Edgar Link	pending
img102364508_13.jpg	Edgar Link	pending
img102364508_14.jpg	Edgar Link	pending
img102364508_15.jpg	Edgar Link	pending
img102364508_16.jpg	Edgar Link	pending
img102364508_17.jpg	Edgar Link	pending
img102364508_18.jpg	Edgar Link	pending
img102364508_2.jpg	Edgar Link	pending
img102364508_3.jpg	Edgar Link	pending
img102364508_4.jpg	Edgar Link	pending
img102364508_5.jpg	Edgar Link	pending
img102364508_6.jpg	Edgar Link	pending
img102364508_7.jpg	Edgar Link	pending
img102364508_8.jpg	Edgar Link	pending
img102364508_9.jpg	Edgar Link	pending
img118948569_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FNCH
Finch Therapeutics Group, Inc. Stock $fnch

2022 Q1 Form 10-K Financial Statement

#000095017022005243 Filed on March 31, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FNCH Finch Therapeutics Group, Inc. Stock $fnch

2022 Q1 Form 10-K Financial Statement

#000095017022005243 Filed on March 31, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FNCH
Finch Therapeutics Group, Inc. Stock $fnch